Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2023-08-03 Board/Management Inform…
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Formation of Clinical Advisory Board
Board/Management Information Classification · 99% confidence The document is dated August 3, 2023, and is distributed via RNS (RNS Number : 1362I), which is the news service of the London Stock Exchange. The content announces the formation of a Clinical Advisory Board to support the adoption of their diagnostic product, KidneyintelX.dkd. This is a specific corporate announcement regarding strategic development and expert engagement, not a primary financial report (like 10-K or IR), a management discussion (MDA), or an earnings release (ER). Since it is a formal, non-standard announcement distributed through the regulatory news service (RNS), and it doesn't fit the specific categories like Board/Management changes (MANG) or Capital changes (CAP), the most appropriate classification is the general regulatory announcement fallback category, RNS.
2023-08-03 English
Vector Pharma Middle East Distribution Agreement
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated July 21, 2023. It announces a commercial distribution agreement for a medical product (kidneyintelX.dkd™) in the Middle East. The text concludes with standard disclaimers, contact information for brokers, and a footer explicitly stating, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a regulatory news service announcement, which falls under the general category of Regulatory Filings (RNS) or, more specifically, a general announcement that doesn't fit the other defined categories like ER, CT, or DIV. Since it is a general, timely announcement distributed via the RNS system, RNS is the most appropriate classification.
2023-07-21 English
Issue of Shares - Replacement
Share Issue/Capital Change Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states it is an amendment to a previous announcement released under RNS No 1495G. The content details the repayment of a convertible bond through the 'Issue of Shares' (issuing 1,052,422 new ordinary shares) and provides details on total voting rights post-admission to trading on AIM. This is a corporate action announcement related to capital structure and share issuance, which falls under the 'Share Issue/Capital Change' category (SHA). Although it is an RNS announcement, the specific nature of the content (share issuance/capital change) makes SHA a more precise classification than the general RNS fallback.
2023-07-17 English
Issue of Shares
Share Issue/Capital Change Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content details the 'Issue of Shares' to repay a convertible bond, resulting in a change to the total number of voting rights. This action—issuing new shares and updating the total share count—falls directly under the definition of a Share Issue/Capital Change (SHA). Although it is distributed via RNS, the core subject matter is a capital structure change, making SHA the most specific classification over the general RNS fallback.
2023-07-17 English
KidneyIntelX evidence presented at ADA
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and the date '07 July 2023', indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details the release of late-breaking clinical data at a scientific conference (American Diabetes Association Scientific Sessions) regarding their product, KidneyIntelX. This is a press release format announcing scientific/clinical updates and business developments, rather than a formal statutory filing like a 10-K or a comprehensive quarterly report (IR). Since it is a general regulatory announcement that doesn't fit the specific categories like ER (Earnings Release), DIV (Dividend Notice), or MANG (Management Change), the most appropriate classification is the general regulatory announcement category, RNS.
2023-07-07 English
Grant of Share Options
Share Issue/Capital Change Classification · 99% confidence The document is an RNS announcement dated 06 July 2023 from Renalytix PLC. The content explicitly details the 'Grant of Share Options' to senior management and directors, including the number of options, exercise price, and vesting schedules. This type of announcement, concerning insider transactions or executive compensation/incentives, often falls under specific categories. While it relates to management compensation (DEF 14A), the primary action described is the granting of options, which is a form of capital/financing activity or a specific insider transaction disclosure. However, the document is structured as a formal regulatory news service (RNS) release, indicated by the 'RNS Number' header and the nature of the disclosure (granting options to directors/executives). Director's Dealing (DIRS) typically covers personal share transactions, not option grants to executives as part of a plan, although there is overlap. Since this is a formal regulatory announcement detailing the issuance of share options to management, it fits best under Capital/Financing Update (CAP) as it directly impacts the capital structure/incentive pool, or potentially Regulatory Filings (RNS) as a general disclosure. Given the specific nature of granting options to key personnel, which is a significant corporate action related to employee incentives and capital, CAP is a strong candidate. However, the document is clearly formatted as an RNS release and details insider/director-related activity (related party transactions pursuant to AIM Rule 13). Since the definitions do not have a specific code for 'Share Option Grant to Insiders', and it is a formal regulatory announcement, RNS is the most appropriate fallback/general category for this type of specific corporate event disclosure that isn't a full financial report or a simple dividend notice. The document length (24k chars) suggests it is the full announcement, not just a brief notice of publication (RPA). I will classify it as RNS as it is a standard regulatory news service filing detailing a corporate action.
2023-07-06 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.